Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiethylperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | MC3R | P41968 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiethylperazine SCHEMBL29507072 | 1.00 | HTR1A (1.00) | HTR1AADRA2ADRD2ADRA2CSLC6A2 | |
| Thiethylperazine SCHEMBL49124 | 1.00 | HTR1A (1.00) | HTR1AADRA2ADRD2ADRA2CSLC6A2 | |
| Thiethylperazine SCHEMBL41676 | 0.91 | HRH1 (0.83) | HTR1AADRA2ADRD2ADRA2CSLC6A2 | |
| Thiethylperazine SCHEMBL30903918 | 0.91 | HRH1 (0.83) | HTR1AADRA2ADRD2ADRA2CSLC6A2 | |
| Thiethylperazine SCHEMBL10624613 | 0.91 | HRH1 (0.83) | HTR1AADRA2ADRD2ADRA2CSLC6A2 | |
| Thiethylperazine SCHEMBL29430925 | 0.91 | HRH1 (0.83) | HTR1AADRA2ADRD2ADRA2CSLC6A2 | |
| Thiethylperazine SCHEMBL41678 | 0.91 | HRH1 (0.83) | HTR1AADRA2ADRD2ADRA2CSLC6A2 | |
| Thiethylperazine SCHEMBL17079861 | 0.91 | HRH1 (0.83) | HTR1AADRA2ADRD2ADRA2CSLC6A2 | |
| Thiethylperazine SCHEMBL13724994 | 0.90 | SLC6A2 (0.80) | HTR1AADRA2ADRD2ADRA2CSLC6A2 | |
| Thiethylperazine SCHEMBL41677 | 0.90 | ADRA2A (0.80) | HTR1AADRA2ADRD2ADRA2CSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| EP-4633602-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | Nanexa AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312275-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| CN-119998661-A | Identifying a subject suffering from or at risk of developing Alzheimer's dementia | 免疫基因股份公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4536179-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | Nanexa AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| US-20250073219-A1 | NEW COMPOSITION COMPRISING IMMUNOMODULATORY DRUG | NANEXA AB (SE) | 2025-03-06 | — | — | US | disclosed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | disclosed |
| WO-2024256696-A1 | NEW INJECTABLE PHARMACEUTICAL DEPOT COMPOSITIONS | NANEXA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4351530-A1 | NEW FORMULATIONS COMPRISING AZACITIDINE | Nanexa AB (SE) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351529-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | Nanexa AB (SE) | 2024-04-17 | — | — | EP | disclosed |
| CN-117715628-A | New formulations comprising biologically active drugs | 南爱克萨股份公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023237897-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022258985-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258988-A1 | NEW COMPOSITION COMPRISING IMMUNOMODULATORY DRUG | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258987-A1 | NEW FORMULATIONS COMPRISING AZACITIDINE | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | DRD2 3871/4885HTR1A 2576/4885ADRA2A 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.